Although the two groups were similar when it came to previous statin or antiplatelet treatment, history of diabetes mellitus, hypertension, tobacco use and previous coronary artery disease, it was observed that COVID-19-era patients had more frequent coronary thrombosis and a higher need of glycoproteins IIb/IIIa inhibitors treatment. This evidence concerns the gene ART4 and diabetes mellitus.